In short

We won Case T-201/21 Covington & Van Vooren vs European Commission.  But why did we litigate?  Why did we ask to see how the member states voted on an EU implementing act?  A short background story, worth a few minutes of your time if interested in the EU as a democracy… 

The context

In 2017, the European Food Safety Authority (EFSA) adopted an opinion expressing safety concerns over Hydroxy Anthracene Derivatives (HADs).  HADs occur naturally in plants like cabbage, sprouts, rhubarb, etc.  They taste bitter and are a defence mechanism of the plant against bugs.  In humans, in high concentrations HADs have a laxative effect.

In 2018, the Commission starts work on banning foods with high concentrations of HADs and laxative effect, through a draft Implementing Act.  To be adopted, these kinds of administrative Acts require a positive vote by a Committee composed of the 27 EU Member States. 

By 2020 the draft Implementing Act had expanded in scope and would ban certain HADs altogether.  The ban itself is being challenged in four parallel annulment proceedings (with hearings taking place over the next few weeks), but that’s another story.

The vote

Not all member states agreed with the expanded scope of the draft implementing act. There was quite some back and forth in the Committee, but by 5 November 2020, the Commission pushed for a vote, using the written procedure (remember that, this matters).

The voting sheet for November 2022 shows that 22 member states voted in favour and five member states against.  This means that a Qualified Majority Vote (QMV) had been reached, although a “blocking minority” against the draft Act was just a hair away.  And so the draft ban became law in April 2021.  

But for those who’d closely followed the process, something was off.  Through informal conversations, it seemed that at least one member state had abstained? Why did this not show up in the voting sheet?  And could this abstention have tilted the blocking minority the other way- so that the Act would not have been adopted?  These questions were why we filed the access request under the EU Transparency Regulation.  We wanted to see which member states voted in what way, to double check if and how QMV had indeed been reached.  Then the plot thickened.  We were refused access to 21 votes in favour, not 22 as indicated on the voting sheet.  So this suggested that there was an abstention counted as a vote in favour- but by which country?  When our request for access to the member states twenty-two individual votes was refused, we decided to litigate and brought Case T-201/21.

Public vote = democracy 101

In T-201/21, we had argued that the vote of a member state in an EU context is intrinsically public.  As the exercise of sovereignty by a country, leading to legally binding acts, it cannot be considered an “opinion” that the Commission can refuse to disclose.  Unfortunately the General Court did not accept our argument.  The Court considers that a vote in comitology is “preparatory” to the final implementing act, and therefore access can be refused.  But the Court did agree there is no general presumption that the member states’ votes are confidential.  For the Court, any refusal to release the votes should be duly justified as to how it negatively impacts the decision making process. Let’s see what happens next- will this go on appeal or will we see the votes?  In our view, anyone should be able to check the member states’ votes on any binding EU act.  That is just democracy 101.

Photo of Bart Van Vooren Bart Van Vooren

Bart Van Vooren has a broad life sciences practice supporting innovative pharmaceutical, food, medtech and biotech companies on EU regulatory, commercial and strategic policy assignments. He is widely recognized for his expertise on general EU law and procedure, as well as his extensive…

Bart Van Vooren has a broad life sciences practice supporting innovative pharmaceutical, food, medtech and biotech companies on EU regulatory, commercial and strategic policy assignments. He is widely recognized for his expertise on general EU law and procedure, as well as his extensive litigation experience before the EU Court of Justice in dozens of cases.

Over the past seven years, Bart has developed a niche practice on compliance with the Biodiversity Convention and the Nagoya Protocol, a set of rules to combat bio-piracy worldwide. He has accumulated unique, practical experience in dozens of jurisdictions around the world, and has handled everything from benefit-sharing negotiations, over compliance programs, to inspections by authorities.

Finally, Bart has an active pro bono practice assisting NGOs defending the human rights of persons with a disability through strategic litigation.

During his previous professional career, Bart was a professor of EU law at the University of Copenhagen and published a couple of books with Oxford and Cambridge University Press. His academic swan song was the (now leading) textbook republished in 2020 by his former academic colleagues in 2nd edition: EU External Relations Law, available from Hart Publishing.